Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Viberzi cases. Here at Leading Justice, we can custom-tailor your firm’s Viberzi advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Viberzi advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is reviewed to determine whether it is eligible for another type of claim. By using advanced approaches to target contacts specifically related to Viberzi use and side effects like pancreatitis and sphincter of Oddi spasms, Leading Justice will increase your firm’s Viberzi caseload. If you are interested in helping victims of alleged Viberzi side effects, our direct advertising strategies and extensive consumer reach give you the competitive edge and confidence you need to allocate your full budget, knowing your money is being used in the best way possible.
Each and every law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. While our experience working with plaintiff law firms helps us recognize a great case when we see one, we will tailor our Viberzi case intake specifications to the exact criteria you are seeking. So, if your firm has specific Viberzi qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Viberzi data with no chance of fraud.
Viberzi Side Effect Litigation
Viberzi (eluxadoline) is a prescription medication approved to treat irritable bowel syndrome with diarrhea (IBS-D) in adults experiencing loose or watery stools at least 25 percent of the time. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2015, and it works by activating opioid receptors in the gut to reduce bowel contractions, leading to less diarrhea and relief from abdominal pain. During Viberzi’s first year on the market, the IBS-D drug was dispensed to approximately 64,000 patients with irritable bowel syndrome, and it wasn’t until 2017, two years after the drug garnered approval from the FDA, that it became evident that Viberzi treatment may increase the risk of pancreatitis and a condition known as sphincter of Oddi spasms in users, among other serious side effects.
In a drug safety communication issued by the FDA in March 2017, the agency warned consumers and the medical community about the potential risk of pancreatitis possibly leading to hospitalization and death associated with Viberzi treatment. According to federal regulators, as of February 2017, the FDA has received 120 reports of adverse events linked to Viberzi, including 76 hospitalizations and two deaths, one from pancreatitis and one from sphincter of Oddi spasms. Pancreatitis and other side effects from Viberzi appear to be most prevalent in patients without a gallbladder, and the FDA has warned that Viberzi treatment is not appropriate in this population. As Viberzi users across the country become aware of the potential for the IBS-D drug to cause life-threatening side effects, product liability lawsuits are expected to be brought against its manufacturer, Allergan, in the coming months and years.